Isolates of Cryptococcus Neoformans from Non-HIV and Non-Transplant Hospitalized Patients

Updata:01-01-1970

Source:
By:Yun Xi, Peng Zhao

DOI: https://doi.org/10.30564/jams.v1i2.36

Abstract:

A retrospective cross-sectional study for patients with confirmed Cryptococcus neoformans meningitis (CM) in non-HIV-infected and non-transplant hosts in two class-A tertiary hospitals in Guangzhou, China is reported. 181 CM patients were enrolled during the study period, 48% (87/181) of which died. Underlying diseases were risk factor associated with higher mortality, among which diabetes mellitus ranked first for the incidence of CM. The mortality was not related to antifungal drug susceptibility. All strains were considered susceptible to amphotericin B, although interpretative breakpoints for amphotericin B have not yet been established. According to the CLSI guidelines, most of the strains in our study were susceptible to voriconazole, fluconazole, fluorocytosine and dose-dependently susceptible to itraconazle.

References:

[1] J.R. Perfect, W.E. Dismukes, F. Dromer, et al. Clinical Practice Guidelines for the Management of Cryptococcal Disease: 2010 Update by the Infectious Diseases Society of America[J]. Clin Infect Dis, 2010, 50(3):291-322. [2] B.J. Park, K.A. Wannemuehler, B.J. Marston, et al. Estimation of the Current Global Burden of Cryptococcal Meningitis among Persons Living with HIV/AIDS[J]. AIDS, 2009, 23(4):525-530. [3] J. Guinea, F. Hagen, T. Pelaez, et al. Antifungal Susceptibility, Serotyping, and Genotyping of Clinical Cryptococcus Neoformans Isolates Collected during 18 Years in a Single Institution in Madrid, Spain[J]. Med Mycol, 2010, 48(7):942-948. [4] J.S. Tan, J.L. Anderson, C. Watanakunakorn, et al. Neutrophil Dysfunction in Diabetes Mellitus[J]. J Lab Clin Med, 1975, 85(1):26-33. [5] C. Yoon, R.M. Gulick, D.R. Hoover, et al. Case-control Study of Diabetes Mellitus in HIV-infected Patients[J]. J Acquir Immune Defic Syndr, 2004, 37(4):1464-1469. [6] E. Canton, A. Espinel-Ingroff, J. Peman. Trends in Antifungal Susceptibility Testing Using CLSI Reference and Commercial Methods[J]. Expert Rev Anti Infect Ther, 2009, 7(1):107-119. [7] A.M. Almeida, M.T. Matsumoto, L.C. Baeza, et al. Molecular Typing and Antifungal Susceptibility of Clinical Sequential Isolates of Cryptococcus Neoformans from Sao Paulo State, Brazil[J]. FEMS Yeast Res, 2007, 7(1):152-164.

Tags: